Published in Medical Letter on the CDC and FDA, September 12th, 2004
Revenues for the June 30, 2004, quarter were $92.9 million, a 23% increase over the quarter ended June 30, 2003, excluding the impact of nonrecurring revenues of approximately $5.0 million related to the severe acute respiratory syndrome (SARS) outbreak in China in fiscal 2003. Including SARS-related revenue in the quarter ended June 2003, revenues increased by 15%.
Income from operations and net income for the June 30, 2004, quarter grew to $24.5 million and $15.9 million respectively, an increase of 32% and 17%. Earnings per share, on a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.